Half-year report · HY
7730.TEDINET S100XYSX
Period2025-09-01 → 2026-02-28
Filed2026-04-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.1bn | 2025-09-01 → 2026-02-28 | Cons. | Net sales |
| Revenue | ¥30.0bn | 2024-09-01 → 2025-08-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.8bn | 2024-09-01 → 2025-02-28 | Cons. | Net sales |
| Operating income | ¥5.1bn | 2025-09-01 → 2026-02-28 | Cons. | Operating income |
| Operating income | ¥4.2bn | 2024-09-01 → 2025-02-28 | Cons. | Operating income |
| Ordinary income | ¥5.6bn | 2025-09-01 → 2026-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥8.3bn | 2024-09-01 → 2025-08-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2024-09-01 → 2025-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥5.6bn | 2025-09-01 → 2026-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥4.3bn | 2024-09-01 → 2025-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.9bn | 2025-09-01 → 2026-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.6bn | 2024-09-01 → 2025-08-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.9bn | 2024-09-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.9bn | 2025-09-01 → 2026-02-28 | Cons. | Profit loss |
| Net income | ¥2.9bn | 2024-09-01 → 2025-02-28 | Cons. | Profit loss |
| Total assets | ¥61.5bn | at 2026-02-28 | Cons. | Assets |
| Total assets | ¥58.0bn | at 2025-08-31 | Cons. | Assets |
| Total assets | ¥58.3bn | at 2025-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2026-02-28 | Cons. | Liabilities |
| Total liabilities | ¥4.4bn | at 2025-08-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.7bn | at 2026-02-28 | Cons. | Net assets |
| Net assets / equity | ¥53.6bn | at 2025-08-31 | Cons. | Net assets |
| Net assets / equity | ¥53.4bn | at 2025-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥22.8bn | at 2026-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.4bn | at 2025-08-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.9bn | at 2026-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.4bn | at 2025-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.0bn | at 2024-08-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.3bn | 2025-09-01 → 2026-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.0bn | 2024-09-01 → 2025-08-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.0bn | 2024-09-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥541m | 2025-09-01 → 2026-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.2bn | 2024-09-01 → 2025-08-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.6bn | 2024-09-01 → 2025-02-28 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.3bn | 2025-09-01 → 2026-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.9bn | 2024-09-01 → 2025-08-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.3bn | 2024-09-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.58 | 2025-09-01 → 2026-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.14 | 2024-09-01 → 2025-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.85 | 2024-09-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 92.2% | at 2026-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.4% | at 2025-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.6% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 32
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-09-01 → 2026-02-28 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-09-01 → 2026-02-28 | ¥0 |
| Dentalreportable segment | revenue | 2025-09-01 → 2026-02-28 | ¥5.3bn |
| Dentalreportable segment | revenue external | 2025-09-01 → 2026-02-28 | ¥5.3bn |
| Dentalreportable segment | segment profit | 2025-09-01 → 2026-02-28 | ¥1.0bn |
| Eyeless Needlereportable segment | revenue | 2025-09-01 → 2026-02-28 | ¥5.9bn |
| Eyeless Needlereportable segment | revenue external | 2025-09-01 → 2026-02-28 | ¥5.9bn |
| Eyeless Needlereportable segment | revenue intersegment | 2025-09-01 → 2026-02-28 | ¥0 |
| Eyeless Needlereportable segment | segment profit | 2025-09-01 → 2026-02-28 | ¥2.4bn |
| Surgicalreportable segment | revenue | 2025-09-01 → 2026-02-28 | ¥4.9bn |
| Surgicalreportable segment | revenue external | 2025-09-01 → 2026-02-28 | ¥4.9bn |
| Surgicalreportable segment | segment profit | 2025-09-01 → 2026-02-28 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-09-01 → 2026-02-28 | ¥16.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-09-01 → 2026-02-28 | ¥16.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-09-01 → 2026-02-28 | ¥0 |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-09-01 → 2026-02-28 | ¥5.1bn |
| Reconciling Itemsreconciling | revenue | 2024-09-01 → 2025-02-28 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-09-01 → 2025-02-28 | ¥0 |
| Dentalreportable segment | revenue | 2024-09-01 → 2025-02-28 | ¥4.5bn |
| Dentalreportable segment | revenue external | 2024-09-01 → 2025-02-28 | ¥4.5bn |
| Dentalreportable segment | segment profit | 2024-09-01 → 2025-02-28 | ¥460m |
| Eyeless Needlereportable segment | revenue | 2024-09-01 → 2025-02-28 | ¥5.6bn |
| Eyeless Needlereportable segment | revenue external | 2024-09-01 → 2025-02-28 | ¥5.6bn |
| Eyeless Needlereportable segment | revenue intersegment | 2024-09-01 → 2025-02-28 | ¥0 |
| Eyeless Needlereportable segment | segment profit | 2024-09-01 → 2025-02-28 | ¥2.1bn |
| Surgicalreportable segment | revenue | 2024-09-01 → 2025-02-28 | ¥4.7bn |
| Surgicalreportable segment | revenue external | 2024-09-01 → 2025-02-28 | ¥4.7bn |
| Surgicalreportable segment | segment profit | 2024-09-01 → 2025-02-28 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-09-01 → 2025-02-28 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-09-01 → 2025-02-28 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-09-01 → 2025-02-28 | ¥0 |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-09-01 → 2025-02-28 | ¥4.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Notes regarding unoperated land related costs (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |